Jetty A Overbeek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7629225/publications.pdf

Version: 2024-02-01

17	360	9	17
papers	citations	h-index	g-index
18	18	18	681 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: A large multinational cohort study. Diabetes, Obesity and Metabolism, 2020, 22, 1607-1618.	4.4	118
2	Type 2 Diabetes Mellitus Treatment Patterns Across Europe: A Population-based Multi-database Study. Clinical Therapeutics, 2017, 39, 759-770.	2.5	64
3	Risk of dipeptidyl peptidaseâ€4 (DPPâ€4) inhibitors on siteâ€specific cancer: A systematic review and metaâ€analysis. Diabetes/Metabolism Research and Reviews, 2018, 34, e3004.	4.0	49
4	Sex- and site-specific differences in colorectal cancer risk among people with type 2 diabetes. International Journal of Colorectal Disease, 2019, 34, 269-276.	2.2	25
5	Type 2 Diabetes, but Not Insulin (Analog) Treatment, Is Associated With More Advanced Stages of Breast Cancer: A National Linkage of Cancer and Pharmacy Registries. Diabetes Care, 2019, 42, 434-442.	8.6	19
6	Factors Associated with Type 2 Diabetes Mellitus Treatment Choice Across Four European Countries. Clinical Therapeutics, 2017, 39, 2296-2310.e14.	2,5	15
7	Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The Netherlands. Pharmacoepidemiology and Drug Safety, 2020, 29, 296-305.	1.9	12
8	Dupuytren's contracture: a retrospective database analysis to determine hospitalizations in the Netherlands. BMC Research Notes, 2011, 4, 402.	1.4	11
9	Burden of Exacerbations in Patients with Moderate to Very Severe COPD in the Netherlands: A Real-life Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 132-143.	1.6	10
10	Clinical effectiveness of liraglutide vs basal insulin in a realâ€world setting: Evidence of improved glycaemic and weight control in obese people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 2093-2102.	4.4	10
11	Impact of EU regulatory label changes for diclofenac in people with cardiovascular disease in four countries: Interrupted time series regression analysis. British Journal of Clinical Pharmacology, 2021, 87, 1129-1140.	2.4	9
12	Costs of hospital events in patients with metastatic colorectal cancer. Journal of Medical Economics, 2011, 14, 656-661.	2.1	6
13	Use of intravenous iron and risk of anaphylaxis: A multinational observational postâ€authorisation safety study in Europe. Pharmacoepidemiology and Drug Safety, 2021, 30, 1447-1457.	1.9	5
14	Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands: An interrupted time series regression analysis. Pharmacoepidemiology and Drug Safety, 2021, 30, 482-491.	1.9	3
15	Respiratory morbidity, healthcare resource use, and cost burden associated with extremely preterm birth in The Netherlands. Journal of Medical Economics, 2021, 24, 1290-1298.	2.1	2
16	No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study. Scientific Reports, 2020, 10, 586.	3.3	1
17	Infliximab use in the Netherlands: Uptake and characteristics of originator and biosimilars over time. British Journal of Clinical Pharmacology, 2021, , .	2.4	1